Journal
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 42, Issue 2, Pages 132-141Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/CCLM.2004.025
Keywords
activated protein C; disseminated intravascular coagulation; endothelial cell injury; neutrophils; sepsis; tumor necrosis factor-alpha
Categories
Ask authors/readers for more resources
Activated protein C (APC), a natural anticoagulant, is formed from protein C by the action of the thrombinthrombomodulin (TM) complex on the endothelial cell surface. Endothelial protein C receptor augments the activation of protein C by the thrombin/TM system. APC inactivates the activated form of coagulation factors V and VIII in the presence of protein S. Administration of APC reduced the pulmonary vascular injury and hypotension as well as the coagulation abnormalities by inhibiting production of the tumor necrosis factor-alpha (TNF-alpha) in rats given endotoxin (ET). These therapeutic effects of APC could not be attributed to its anticoagulant effects. APC inhibited ET induced TNF-alpha production in human monocytes by inhibiting activation of nuclear factor k-B and activator protein-1 in vitro. Administration of the human plasmaderived APC ameliorated coagulation abnormalities without any adverse effects in patients with disseminated intravascular coagulation (DIC). Recombinant APC was reported to reduce the mortality of patients with severe sepsis, and the therapeutic effect was more marked in such patients with overt DIC than those without it. These observations strongly suggest that APC plays important roles in the regulation of inflammation as well as coagulation. Both antiinflammatory and anticoagulant properties of APC might contribute to the therapeutic usefulness in patients with severe sepsis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available